首页> 外文会议>International Symposium on Atherosclerosis >PPARa controlling HDL metabolism and atherosclerosis
【24h】

PPARa controlling HDL metabolism and atherosclerosis

机译:PPARA控制HDL代谢和动脉粥样硬化

获取原文

摘要

Low serum high-density lipoprotein (HDL) cholesterol concentrations are a feature of the metabolic syndrome that is increasingly being recognized as an important risk factor for cardiovascular disease. HDL is a key mediator of reverse cholesterol transport (RCT), a pathway transporting cholesterol from extrahepatic cells and tissues to the liver for excretion HDL metabolism is controlled by the interaction of its protein constituents, the apolipoproteins, such as apoA-I and apoA-II, with different enzymes (LCAT, HL, LPL), transfer proteins (CETP, PLTP.) and lipoprotein receptors (ABCA-1, SR-BI, ). The level of expression of most of these proteins is partly controlled at the level of transcription by transcription factors, among which ate the nuclear receptors Nuclear receptors are activated by small lipophilic signalling molecules Among these nuclear receptors, peroxisome proliferator-activated receptors were first identified to play a role in the control of lipid metabolism.In this paper, we will focus on the role of PPARa in HDL metabolism, its molecular action mechanism and its potential as pharmacological targets for future drug discovery.
机译:低血清高密度脂蛋白(HDL)胆固醇浓度是代谢综合征的特征,越来越被认为是心血管疾病的重要危险因素。 HDL是反向胆固醇转运(RCT)的关键介体,通过其蛋白质成分的相互作用,载脂蛋白(例如apoa-i和apoo-)控制从脱胸腺细胞和组织到肝脏的肝脏与肝脏组织的途径。 II,具有不同酶(LCAT,HL,LPL),转移蛋白(CETP,PLTP。)和脂蛋白受体(ABCA-1,SR-BI)。大多数这些蛋白质的表达水平在转录因子的转录水平上被部分控制,其中核受体核受体在这些核受体中的小型亲脂性信号分子激活,最初确定过氧化物酶体增殖物激活的受体在对脂质代谢的控制中发挥作用。本文,我们将专注于PPARA在HDL代谢中的作用,其分子作用机制及其作为未来药物发现的药理目标的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号